Hyperexpensive cancer drugs are putting pressure on U.S. oncologists, who have to deal with increasing delays and denials of reimbursement, as well as payment conflicts with drug distributors. Doctors say the trend has influenced their treatment decisions, prompting some to prescribe cheaper alternatives to help patients avoid pricey medicines. As a result, the median income of oncologists in 2006 and 2007 was roughly flat after nearly 10 years of increasing salaries, according to the Medical Group Management Association.

Related Summaries